Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus

Background: Mycobacterium abscessus is notorious for being intrinsically resistant to most antibiotics. Antibiotic efflux is one of the mechanisms used by M. abscessus to pump out antibiotics from their cells. Inhibiting efflux pumps (EPs) can be an attractive strategy to enhance the activity of drugs. The objective of this study is to determine the activity of EP inhibitors (EPIs) to enhance the efficacy of the new drug bedaquiline against M. abscessus clinical isolates. Methods: A total of 31 phenotypically and genotypically identified M. abscessus subsp. abscessus, M. abscesss subsp. massiliense, and M. abscessus subsp. bolletii clinical isolates were studied. The contribution of EPs was determined by investigating the minimum inhibitory concentration (MIC) levels of bedaquiline reduction in the absence and presence of EPIs verapamil and reserpine using the resazurin microtiter assay. Results: The observed bedaquiline MIC reduction by verapamil was observed in 100% isolates and by reserpine in 54.8% isolates. Bedaquiline MIC was 4–32-fold using verapamil with M. abscessus subsp. bolletii showing the highest fold change and between 2- and 4-fold using reserpine. Conclusions: The results obtained in this study confirm that bedaquiline MIC decreased in the presence of EPIs verapamil and reserpine in clinical isolates of M. abscessus. Verapamil was the most effective EPI. As shown in previous studies, verapamil may have clinical potential as adjunctive therapy to enhance the effect of bedaquiline.

• Publication year

  2020

• Venue

  International Journal of Mycobacteriology

• Publication date

  2020-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/ijmy.ijmy_181_19PMID 32474492
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages

  2019cited by this paper
• Efflux pump inhibitors for bacterial pathogens: From bench to bedside

  2019cited by this paper
• In silico and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in Mycobacterium abscessus.

  2019cited by this paper
• In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.

  2019cited by this paper
• In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria

  2017cited by this paper
• Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections

  2017cited by this paper
• Multidrug-resistant Mycobacterium abscessus threatens patients with cystic fibrosis.

  2017cited by this paper
• Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis

  2017cited by this paper
• GenoType NTM-DR for Identifying Mycobacterium abscessus Subspecies and Determining Molecular Resistance

  2016cited by this paper
• Structural basis for the blockade of MATE multidrug efflux pumps

  2015cited by this paper
• Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.

  2015cited by this paper
• Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.

  2015cited by this paper
• Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.

  2014cited by this paper
• The Efflux Pump Inhibitor Timcodar Improves the Potency of Antimycobacterial Agents

  2014cited by this paper
• Verapamil Increases the Bactericidal Activity of Bedaquiline against Mycobacterium tuberculosis in a Mouse Model

  2014cited by this paper
• Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

  2014cited by this paper
• Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

  2013cited by this paper
• Mycobacterium abscessus: a new antibiotic nightmare.

  2012cited by this paper
• Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors.

  2011cited by this paper
• Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates

  2011cited by this paper
• Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.

  2011cited by this paper
• Importance of the Efflux Pump Systems in the Resistance of Mycobacterium tuberculosis to Fluoroquinolones and Linezolid

  2007influential reference
• Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria.

  2006influential reference
• Resazurin Microtiter Assay Plate Testing of Mycobacterium tuberculosis Susceptibilities to Second-Line Drugs: Rapid, Simple, and Inexpensive Method

  2003cited by this paper
• Systemic availability of oral verapamil and effect on PR interval in man.

  1981cited by this paper
• Clinical toxicity of reserpine in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program

  1976cited by this paper

• Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.

  2026cites this paper
• Role of efflux pump inhibitors in enhancing the effect of bedaquiline on M. tuberculosis.

  2026cites this paper
• A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus

  2025cites this paper
• Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends

  2025cites this paper
• Revolutionizing non-tuberculous mycobacteria research: Advances in molecular diagnostics, phylogenetics, and clinical management.

  2025cites this paper
• Evaluation of the interaction and synergy potential of bedaquiline and clarithromycin in combination with efflux pump inhibitors in clinical isolates of Mycobacterium abscessus complex.

  2025cites this paper
• Colorimetric methods for detecting antimicrobial resistant mycobacteria: An overview.

  2025cites this paper
• Current Understanding of Mycobacterium tuberculosis Drug Resistances and Diagnostics in Indonesia: A Review

  2024cites this paper
• Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

  2023cites this paper
• Pipeline of anti‐Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities

  2021cites this paper
• Antimicrobial susceptibility profiles of Mycobacterium abscessus complex isolated from respiratory specimens in Shanghai, China.

  2021cites this paper
• Host‐directed therapy to combat mycobacterial infections

  2021cites this paper
• Evaluation of the MGIT 960/EpiCenter TB eXiST system for drug susceptibility testing for Mycobacterium abscessus complex

  2020cites this paper
• Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?

  2020cites this paper